Free light chains, kappa (κ) lambda (λ), are produced by plasma cells and known to be an important marker in patients with Multiple Myeloma and AL Amyloidosis. The precursor condition to Multiple ...
Background: Diagnosis of monoclonal gammopathies (MGs) is determined by demonstration of a monoclonal immunoglobulin molecule or chain in serum and/or urine. Previous results on immunofixation ...
The analysis of serum free light chains (FLC) is now standard of care in the screening, diagnosis, and monitoring of patients suspected of/having multiple myeloma (MM) or other monoclonal gammopathies ...
Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.
Free light chain (FLC) kappa and lambda Assays for Atellica ® NEPH 630*, BN TM II, and BN ProSpec ® Systems are developed for more reliable managment of patients with monoclonal gammopathies. Improved ...
MM often goes undetected until its later stages because it presents with non-specific symptoms, including fatigue, weight loss, bone pain, and recurrent infections. 2,3 However, better awareness, ...
Current standard modalities for detecting and quantifying monoclonal immunoglobin in patients with cold agglutinin disease lack adequate sensitivity. Heavy chain/light chain assay may be more ...
BIRMINGHAM, England--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has been 510k cleared, following US Food and Drug Administration (FDA) ...
A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients. Background: The latest guidelines for response published by the International Myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback